Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for Rosuvastatin
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemia
Conditions
Hyperlipidemia
Trial Timeline
Nov 11, 2025 → Mar 1, 2027
NCT ID
NCT07216482About Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for Rosuvastatin
Enlicitide + Rosuvastatin + Placebo for Enlicitide + Placebo for Rosuvastatin is a phase 3 stage product being developed by Merck for Hyperlipidemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07216482. Target conditions include Hyperlipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07216482 | Phase 3 | Recruiting |
Competing Products
20 competing products in Hyperlipidemia